Corvus Pharmaceuticals Announces Initial Data from Soquelitinib Clinical Trial in Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) will be Presented at the 68ᵗʰ American Society for Hematology Annual Meeting & Exposition
Globe Newswire•04/11/2026•09:01 ET
0
Key Highlights
- ➤Three ALPS patients completed one year of soquelitinib treatment at 200 mg twice daily
- ➤No grade 3 or 4 adverse events or treatment interruptions occurred
- ➤All three patients discontinued background medications including steroids
- ➤All three patients reported improved ALPS-related systemic symptoms
- ➤Corvus plans longer treatment durations and younger pediatric enrollment
Expert Statements
V. Koneti Rao, MD, FRCPA; Senior Research Physician, Primary Immune Deficiency Clinic (ALPS Clinic) at NIH Clinical Center
“Clinical assessment of soquelitinib, an interleukin-2-inducible T cell kinase (ITK) inhibitor, for treatment of autoimmune lymphoproliferative syndrome (ALPS)-FAS”
Data shows positive one-year safety and efficacy data from three patients enrolled in ongoing Phase 2 clinical trial being led by researchers at the National Institute of Allergy and Infectious Diseases (NIAID)
Safety profile consistent with results from soquelitinib T cell lymphoma and atopic dermatitis clinical trials
Get started
Create a free account to read the full story.